发明名称 |
USE OF NK-1 RECEPTOR ANTAGONISTS AGAINST BENIGN PROSTATIC HYPERPLASIA |
摘要 |
The invention relates to the use of an NK-1 receptor antagonist for the treatment or prevention of benign prostatic hyperplasia (BPH). The preferred NK-1 receptor antagonists are compounds of the general formula (I) wherein the meanings of R, R<1>, R<2>, R<2'>, R<3>, R<4> are explained in the specification and the pharmaceutically acceptable acid addition salts and the prodrugs thereof. Preferred compounds are 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide,3-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-[6-(4-methyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-isobutyramide,2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1 lambda <6>-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide and 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1 lambda <6>-thiomorpholin-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide. The invention also relates to pharmaceutical composition comprising one or more such NK-1 receptor antagonists and a pharmaceutically acceptable excipient for the treatment and/or prevention of benign prostatic hyperplasia. |
申请公布号 |
WO02085458(A2) |
申请公布日期 |
2002.10.31 |
申请号 |
WO2002EP01085 |
申请日期 |
2002.02.02 |
申请人 |
F. HOFFMAN-LA ROCHE AG |
发明人 |
BUSER, SUSANNE;FORD, ANTHONY, P., D., W.;HOFFMANN, TORSTEN;LENZ, BARBARA;SLEIGHT, ANDREW, JOHN;VANKAN, PIERRE |
分类号 |
C07D213/75;A61K31/44;A61K31/455;A61K31/5377;A61K31/541;A61K45/00;A61P13/08;A61P43/00 |
主分类号 |
C07D213/75 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|